{"id":20172,"date":"2012-12-20T10:58:14","date_gmt":"2012-12-20T15:58:14","guid":{"rendered":"http:\/\/brocku.ca\/brock-news\/?p=20172"},"modified":"2018-12-20T13:18:29","modified_gmt":"2018-12-20T18:18:29","slug":"brock-signs-agreement-with-lorus-therapeutics-inc-to-develop-anticancer-drugs","status":"publish","type":"post","link":"https:\/\/brocku.ca\/brock-news\/2012\/12\/brock-signs-agreement-with-lorus-therapeutics-inc-to-develop-anticancer-drugs\/","title":{"rendered":"Brock signs agreement with Lorus Therapeutics Inc. to develop anticancer drugs"},"content":{"rendered":"
\"Brock<\/a>

Brock chemist Tomas Hudlicky will head a research team to develop anticancer drugs for Lorus Therapeutics.<\/p><\/div>\n

The fight against cancer has been bumped up a notch following Brock University’s agreement with Lorus Therapeutics Inc.<\/a> to develop novel anticancer drugs.<\/p>\n

Chemist Tomas Hudlicky<\/a> heads a research team at Brock that has synthesized chemical derivatives of the natural compound pancratistatin.<\/p>\n

Under the agreement, Lorus will test the anticancer activity and drug-like properties of derivatives produced by Hudlicky’s group. The natural compound pancratistatin has been shown to have strong anti-tumor activity against a number of cancers with minimal toxic effects on normal cells.<\/p>\n

Brock University will share jointly with Lorus in new intellectual property created from this partnership.<\/p>\n

The Brock University-Lorus Therapeutics Inc. partnership has been made possible through funding from the Federal Economic Development Agency for Southern Ontario’s Applied Research and Commercialization (ARC) Initiative.<\/p>\n

“This is an exciting new opportunity,” says John Wilson, Brock’s director of Innovation and Commercialization.<\/p>\n

“Professor Hudlicky has an impressive track record commercializing his scientific discoveries, and we are very happy that this new partnership is with Lorus, an innovative company also located in Ontario.”<\/p>\n

Lorus President and CEO Aiping Young said the company looks forward to working with Hudlicky, who is also a Canada Research Chair in Biocatalysis.<\/p>\n

“Tomas and his group have done some ground-breaking work,” said Young, “and we are very pleased to join this effort in developing novel derivatives of pancratistatin, which we believe is a new and exciting approach to cancer treatment.”<\/p>\n","protected":false},"excerpt":{"rendered":"

The fight against cancer has been bumped up a notch following Brock University’s agreement with Lorus Therapeutics Inc. to develop novel anticancer drugs.<\/p>\n","protected":false},"author":13,"featured_media":20175,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3,1],"tags":[642,48,730,3325],"_links":{"self":[{"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/posts\/20172"}],"collection":[{"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/comments?post=20172"}],"version-history":[{"count":2,"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/posts\/20172\/revisions"}],"predecessor-version":[{"id":20176,"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/posts\/20172\/revisions\/20176"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/media\/20175"}],"wp:attachment":[{"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/media?parent=20172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/categories?post=20172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brocku.ca\/brock-news\/wp-json\/wp\/v2\/tags?post=20172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}